TORONTO and DALLAS, Nov. 8, 2024
/CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK)(OTC: PYNKF)
("Perimeter" or the "Company"), a commercial-stage medical
technology company, announced it will report its third
quarter 2024 financial and operating results after market close on
Thursday, November 14, 2024.
Following the announcement, Perimeter management will host a
webcast and conference call to discuss the results and provide a
corporate update.
Third Quarter 2024 Results Conference Call Details:
Date:
Thursday, November 14, 2024
Time:
5:00 pm Eastern Time
Dial-In Numbers:
1-800-717-1738 (Canada and
the United States) or
1-646-307-1865 (International)
The call will also be broadcast live and archived on the
Company's website under "News/Events" in the Investors section.
About Perimeter Medical Imaging AI, Inc.
Based
in Toronto, Canada and
Dallas, Texas, Perimeter Medical
Imaging AI (TSX-V: PINK) (OTC: PYNKF) (FSE: 4PC) is
a medical technology company driven to transform cancer surgery
with ultra-high-resolution, real-time, advanced imaging tools to
address areas of high unmet medical need. Available across the
U.S., our FDA-cleared Perimeter S-Series OCT system provides
real-time, cross-sectional visualization of excised tissues at the
cellular level. The breakthrough-device-designated investigational
Perimeter B-Series OCT with ImgAssist AI represents our
next-generation artificial intelligence technology that is
currently being evaluated in a pivotal clinical trial, with support
from a grant of up to US$7.4 million
awarded by the Cancer Prevention and Research Institute of
Texas. The company's ticker symbol
"PINK" is a reference to the pink ribbons used during Breast Cancer
Awareness Month.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward-Looking Statements
This news release contains
statements that constitute "forward-looking information" within the
meaning of applicable Canadian securities legislation. In this news
release, words such as "may," "would," "could," "will," "likely,"
"believe," "expect," "anticipate," "intend," "plan," "estimate,"
and similar words and the negative form thereof are used to
identify forward-looking statements. Forward-looking information
may relate to management's future outlook and anticipated events or
results and may include statements or information regarding the
future financial position, business strategy and strategic goals,
competitive conditions, research and development activities,
projected costs and capital expenditures, research and clinical
testing outcomes, taxes and plans and objectives of, or involving,
Perimeter. Without limitation, information regarding the potential
benefits of Perimeter S-Series OCT, Perimeter B-Series OCT, and
Perimeter ImgAssist are forward-looking information.
Forward-looking statements should not be read as guarantees of
future performance or results, and will not necessarily be accurate
indications of whether, or the times at or by which, any particular
result will be achieved. No assurance can be given that any events
anticipated by the forward-looking information will transpire or
occur. Forward-looking information is based on information
available at the time and/or management's good-faith belief with
respect to future events and are subject to known or unknown risks,
uncertainties, assumptions, and other unpredictable factors, many
of which are beyond Perimeter's control. Such forward-looking
statements reflect Perimeter's current view with respect to future
events, but are inherently subject to significant medical,
scientific, business, economic, competitive, political, and social
uncertainties and contingencies. In making forward-looking
statements, Perimeter may make various material assumptions,
including but not limited to (i) the accuracy of Perimeter's
financial projections; (ii) obtaining positive results from trials;
(iii) obtaining necessary regulatory approvals; and (iv) general
business, market, and economic conditions. Further risks,
uncertainties and assumptions include, but are not limited to,
those applicable to Perimeter and described in Perimeter's
Management Discussion and Analysis for the year ended December 31, 2023, which is available on
Perimeter's SEDAR+ profile at https://www.sedarplus.ca, and could
cause actual events or results to differ materially from those
projected in any forward-looking statements. Perimeter does not
intend, nor does Perimeter undertake any obligation, to update or
revise any forward-looking information contained in this news
release to reflect subsequent information, events, or circumstances
or otherwise, except if required by applicable laws.
CONTACTS:
Stephen Kilmer
Investor Relations
Telephone: 888-545-6374 or 647-872-4849
Email: skilmer@perimetermed.com
Adrian Mendes
Chief Executive Officer
Toll-free: 888-988-7465 (PINK)
Email: investors@perimetermed.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/perimeter-medical-imaging-ai-to-report-third-quarter-2024-financial-results-and-host-conference-call-on-november-14-2024-302299799.html
SOURCE Perimeter Medical Imaging AI Inc.
